Alexandria Real Estate Faces Class Action for Misleading Statements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm alerts investors that Alexandria Real Estate Equities is facing a class action lawsuit for violations of securities laws during the period from January 27, 2025, to October 27, 2025, which may result in significant investor losses.
- False Statement Allegations: According to the complaint, Alexandria misled the market with false and misleading statements regarding leasing spreads and anticipated occupancy growth for its life-science properties, leading to investor damages once the truth emerged.
- Investor Rights Protection: Affected investors are encouraged to contact the Schall Law Firm before January 26, 2026, to discuss their rights and participate in the lawsuit, indicating the firm's commitment to protecting shareholder interests.
- Litigation Status: The class action has not yet been certified, meaning investors are not currently represented by an attorney, highlighting the importance of timely action to ensure their rights are safeguarded.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 64.78 USD with a low forecast of 30.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
9 Hold
1 Sell
Hold
Current: 53.270
Low
30.00
Averages
64.78
High
104.00
Current: 53.270
Low
30.00
Averages
64.78
High
104.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
